EGFR and breast carcinoma: Resistance to ERBB2-targeted therapy including the use of trastuzumab, an anti-ERBB2 monoclonal antibody, and lapatinib, a small molecule kinase inhibitor of ERBB2 and EGFR, is associated with alternations of signal transduction pathways, apoptosis, and cell cycle control in breast cancer [7].